Targeting CERT sensitizes AML Cells to FLT3 Inhibitors through activating GRP78-ATF6-CHOP Axis
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × DMSO vs 3 × HPA-12 vs 3 × Creon vs 3 × ComboGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axisNature communications · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE280391_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1178294 and SRA study SRP541436. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8596637 DMSO1 DMSO
- GSM8596638 HPA-12-1 HPA-12
- GSM8596639 Creon1 Creon
- GSM8596640 Combo1 Combo
- GSM8596641 DMSO2 DMSO
- GSM8596642 HPA-12_2 HPA-12
- GSM8596643 Creon2 Creon
- GSM8596644 Combo2 Combo
- GSM8596645 DMSO3 DMSO
- GSM8596646 HPA-12_3 HPA-12
- GSM8596647 Creon3 Creon
- GSM8596648 Combo3 Combo
- GSE338135 NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib 75 samples shares flt3, aml, sensitizes
- GSE315549 Targeting UGCG sensitizes AML cells to Venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication 12 samples shares aml, sensitizes, targeting
- GSE289713 Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations 11 samples shares flt3, aml
- GSE241650 Pharmaceutical inhibition of RAS overcomes cytokine mediated resistance to FLT3 inhibition in FLT3-ITD+ AML 76 samples shares flt3, aml
- GSE241646 Pharmaceutical inhibition of RAS overcomes cytokine mediated resistance to FLT3 inhibition in FLT3-ITD+ AML [ATAC-seq] 28 samples shares flt3, aml
- GSE278623 A synergistic interaction between PRMT5 and LSD1 inhibitors in AML 24 samples shares aml, inhibitors
- GSE241989 Immunotherapeutic targeting of surfaceome heterogeneity in AML 18 samples shares aml, targeting
- GSE337663 Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (AML patient samples) 8 samples shares aml, targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.